Cumberland Pharmaceuticals (NASDAQ:CPIX) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research report report published on Sunday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Price Performance

CPIX stock opened at $1.29 on Friday. The company has a market capitalization of $18.19 million, a P/E ratio of -2.19 and a beta of 0.20. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.26 and a current ratio of 1.44. Cumberland Pharmaceuticals has a 52-week low of $1.27 and a 52-week high of $2.36. The business has a 50-day simple moving average of $1.41 and a two-hundred day simple moving average of $1.56.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.